Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Revision of the American Joint Committee on Cancer staging system for breast cancer.
Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Singletary SE, et al. Among authors: theriault rl. J Clin Oncol. 2002 Sep 1;20(17):3628-36. doi: 10.1200/JCO.2002.02.026. J Clin Oncol. 2002. PMID: 12202663
Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual.
Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Singletary SE, et al. Among authors: theriault rl. Surg Clin North Am. 2003 Aug;83(4):803-19. doi: 10.1016/S0039-6109(03)00034-3. Surg Clin North Am. 2003. PMID: 12875597 Review.
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN. Gonzalez-Angulo AM, et al. J Clin Oncol. 2009 Dec 1;27(34):5700-6. doi: 10.1200/JCO.2009.23.2025. Epub 2009 Nov 2. J Clin Oncol. 2009. PMID: 19884543 Free PMC article.
Update: breast cancer guidelines.
Edge S, Theriault R. Edge S, et al. J Natl Compr Canc Netw. 2003 Oct;1 Suppl 3:S-3-8. J Natl Compr Canc Netw. 2003. PMID: 23570131
Multidisciplinary management of breast cancer concurrent with pregnancy.
Keleher AJ, Theriault RL, Gwyn KM, Hunt KK, Stelling CB, Singletary SE, Ames FC, Buchholz TA, Sahin AA, Kuerer HM. Keleher AJ, et al. Among authors: theriault rl. J Am Coll Surg. 2002 Jan;194(1):54-64. doi: 10.1016/s1072-7515(01)01105-x. J Am Coll Surg. 2002. PMID: 11800340 Review.
The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial.
Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, Walters R, Hortobagyi GN. Thomas E, et al. Among authors: theriault rl. J Clin Oncol. 2004 Jun 15;22(12):2294-302. doi: 10.1200/JCO.2004.05.207. J Clin Oncol. 2004. PMID: 15197190 Clinical Trial.
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Buzdar AU, et al. Among authors: theriault rl. J Clin Oncol. 2005 Jun 1;23(16):3676-85. doi: 10.1200/JCO.2005.07.032. Epub 2005 Feb 28. J Clin Oncol. 2005. PMID: 15738535 Clinical Trial.
222 results